Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Market Report 2026

The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market size has grown rapidly in recent years. It will grow from $6.2 billion in 2025 to $7.24 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to limited availability of specialized cdmo services, increasing r&d investment in advanced therapies, early adoption of gene and cell therapies, rising prevalence of complex diseases, growth of small biotech startups.

The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market size is expected to see rapid growth in the next few years. It will grow to $12.55 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to advancements in scalable manufacturing technologies, increasing collaborations between cdmos and pharma, growth of autologous and allogeneic therapies, rising global demand for personalized medicine, expansion into emerging markets. Major trends in the forecast period include rising demand for cdmo services in advanced therapy development, expansion of gene, cell, and tissue engineered therapies, increasing focus on regulatory compliance and quality standards, growth in outsourced manufacturing for biopharmaceutical companies, adoption of scalable and flexible manufacturing platforms.

The rising number of clinical trials is expected to drive the growth of the advanced therapy medicinal products (ATMP) CDMO market in the coming years. Clinical trials are research studies conducted in humans to assess the safety and effectiveness of medical interventions, including drugs, treatments, devices, or preventive measures. The number of clinical trials is increasing to meet the growing demand for innovative therapies and to address a rising global disease burden. As the use of advanced therapy medicinal products expands, the demand for CDMO manufacturing services grows, relying on specialized expertise and infrastructure. Clinical trial data supports the optimization of manufacturing processes, ensuring scalability and maintaining quality to meet larger clinical and commercial needs. For instance, in July 2024, according to the Royal Pharmaceutical Society, a UK-based professional membership organization, 349,019 people were recruited to clinical trials in the UK in 2023/2024, up from 342,390 in 2022/2023. Therefore, the increasing number of clinical trials is contributing to the expansion of the advanced therapy medicinal products CDMO market.

Major companies in the advanced therapy medicinal products CDMO market are focusing on developing advanced cell therapy manufacturing services to address critical challenges in cell therapy production and accelerate the development efforts of their partners. Cell therapy manufacturing services are contract development and manufacturing organization (CDMO) services that range from early preclinical development to late-stage clinical trials and commercialization. For instance, in January 2024, Pluristem Therapeutics Inc., an Israel-based biotech company that transforms cells into therapeutic solutions, launched PluriCDMO, a new business division providing cell therapy manufacturing. It employs a patented bioreactor system that enables 3D cell multiplication, supporting the production of various cell types, including stem cells, induced pluripotent stem cells, exosomes, and immune therapies. PluriCDMO aims to deliver high-quality, essential medicines to patients while maintaining consistent batch-to-batch quality in a scalable and cost-effective manner under good manufacturing practice (GMP) conditions.

In January 2025, Altaris, LLC, a US-based investment firm focused on healthcare and building companies in the medical-product and biotech services sector, acquired Minaris Regenerative Medicine from Resonac Corporation for an undisclosed sum. Through this acquisition, Altaris seeks to strengthen its presence in the advanced therapy medicinal products (ATMP) CDMO sector and accelerate its strategy to scale life-changing cell and gene therapies globally. Minaris Regenerative Medicine is a US-based CDMO offering autologous and allogeneic cell therapy manufacturing services across clinical and commercial stages.

Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Recipharm AB, KBI Biopharma, Takara Bio Inc., Rentschler Biopharma SE, Ajinomoto Co. Inc., ElevateBio LLC, Fujifilm Diosynth Biotechnologies, Axplora Group GmbH, WuXi Advanced Therapies Inc., Celonic Group, Batavia Biosciences B.V., BioCentriq, Cytovance Biologics, Andelyn Biosciences, Genezen, AGC Biologics, ABL Manufacturing, Minaris Regenerative Medicine, Porton Advanced Solutions.

North America was the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the advanced therapy medicinal products CDMO market by raising the cost of imported bioreactors, viral vectors, and specialized reagents, increasing production expenses. Segments such as gene therapy, cell therapy, and tissue-engineered products are particularly impacted, with north america, europe, and asia-pacific regions facing the highest import duties. While tariffs increase operational costs and affect supply chain efficiency, they also encourage local production, innovation in manufacturing processes, and development of domestic CDMO capabilities.

The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market research report is one of a series of new reports that provides advanced therapy medicinal products contract development and manufacturing organization (cdmo) market statistics, including advanced therapy medicinal products contract development and manufacturing organization (cdmo) industry global market size, regional shares, competitors with a advanced therapy medicinal products contract development and manufacturing organization (cdmo) market share, detailed advanced therapy medicinal products contract development and manufacturing organization (cdmo) market segments, market trends and opportunities, and any further data you may need to thrive in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) industry. This advanced therapy medicinal products contract development and manufacturing organization (cdmo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An advanced therapy medicinal product contract development and manufacturing organization (CDMO) is a specialized service provider that supports the development and manufacturing of advanced therapy medicinal products. The purpose of an advanced therapy medicinal product CDMO is to offer the expertise, infrastructure, and resources necessary for the development and production of advanced therapy medicinal products.

The main product types of advanced therapy medicinal products contract development and manufacturing organizations (CDMO) include gene therapy, cell therapy, and tissue-engineered products. Gene therapy involves the introduction, removal, or modification of genetic material within a patient’s cells to treat or prevent disease. This is carried out using viral or non-viral vectors to deliver therapeutic genes to target cells across several phases, including phase I, phase II, phase III, and phase IV, for treating a range of indications such as oncology, cardiology, central nervous system and musculoskeletal disorders, infectious diseases, dermatology, endocrine disorders, metabolic disorders, genetic conditions, immunology and inflammation, ophthalmology, and hematology.

The advanced therapy medicinal product contract development and manufacturing organization (CDMO) market includes revenues earned by entities by providing services such as process development, analytical method development, good manufacturing practice manufacturing, and quality control testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced therapy medicinal products CDMO market also includes sales of bioreactors and fermenters, cryopreservation equipment, and laboratory instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.